---
$id: https://graph.org.ai/products/commodity/51131753
$type: Product
source: UNSPSC
code: "51131753"
title: "Ozagrel sodium"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Ozagrel sodium

**UNSPSC Code**: 51131753
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an enzyme inhibitor and antiplatelet agent C13H11N2O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4X5577N3ET, chemically known as 2-propenoic acid, 3-(4-(1h-imidazol-1-ylmethyl)phenyl)-, sodium salt (1:1), (2e)-, but more generally known as ozagrel sodium, which bears US NIH Compound Identifier 23663942. European Medicines Agency schedules Ozagrel sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03604MIG. Most nations, for tariff and trade purposes, schedule ozagrel sodium under HS 29332990 and SITC 51573. As of Q4 2014, OZAGREL SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CCC1CN2CCNC2)/C=C/C(=O)[O-].[NA+].

